The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index; 9 of the 106 sources its claims cite were checked for support.
Abstract
In the past decade, the number of papers dealing with treatment resistance in depression has increased to a considerable degree. It has recently been discussed whether current definitions of treatment resistance are appropriate: issues of misdiagnosis, diagnostic and biological heterogeneity, and suboptimal therapeutic strategies have been raised [1-3]. However, current conceptualizations of treatment resistance focus on the characteristics of the patient (whether neurobiological assets, or attitudes, or psychiatric comorbidity) for the insufficient effectiveness of antidepressant drugs and omit any reference to the potential iatrogenic effects of treatment [4], as if, in the field of infectious disease, treatment resistance were conceptualized independently of the previous use of antibiotics. \nWe will try to outline some historical developments of the concept of treatment resistance in depression and how a different assessment strategy is required to address current clinical challenges.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 4 Not valid · 68 Not checked · 26 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A particular form of resistance occurs when a drug which resulted in clinical response in previous episodes is no longer effective when it is started again after a drug-free period.”
What the sources say
- Supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) source
The intro passage of our copy (unnumbered section, p. 1) explicitly lists among antidepressant-related clinical phenomena 'lack of response to a previously effective treatment when it is started again after a drug-free period', and the oppositional-tolerance passage (same section) states that when drug treatment ends, oppositional processes may persist 'resulting in appearance of withdrawal symptoms, increased vulnerability to relapse, or resistance if treatment is reinstituted'. The 'Pharmacological Strategies' section reinforces this by treating reinstroduction of the same AD as questionable and noting that tolerance may extend to other drugs of the same class. Thus the cited paper does describe this rechallenge failure as a specific form of resistance arising under oppositional tolerance; the only softening is that the paper frames it within a model using 'may', which the paraphrase drops. (LLM, conf=0.85)
- Not checked yetcites [27] matched to “Authors' response to a critique by Jauhar and Hayes of ‘A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guideline evidence-based?’” (2019) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The return of depressive symptoms during maintenance antidepressant treatment was found to occur in a significant proportion of patients in published trials [26, 28].”
What the sources say
- Partly supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) sourceExperimental — accuracy not yet measured
The introduction of our copy (pp. 257-267, opening section) does list 'the return of depressive symptoms during long-term maintenance' among the clinical phenomena related to AD, but it is presented as a recognized phenomenon credited to Fava [13] (Fava GA, J Clin Psychiatry 2003), with no trial data attached. No passage in our copy reports that published trials found this return in a significant proportion of patients during maintenance treatment; the only during-treatment figure given is in the 'Paradoxical Effects' section, where Fux et al. [23] observed emergent depressive symptoms in 7 of 80 patients (9%) treated for panic disorder with fluvoxamine — a different population, a different framing (paradoxical/oppositional tolerance rather than maintenance relapse), and not a large proportion. Thus the existence of the phenomenon is supported, while the quantitative/trial-level part of the claim is not. (LLM, conf=0.72)
- Not checked yetcites [28] matched to “A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)” (2012) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Resistance may also ensue with loss of clinical effect in a patient who previously responded to antidepressant drug treatment.”
What the sources say
- Supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) source
The “Lack or Loss of Efficacy” section says an antidepressant may lose effectiveness after a period of treatment, implying an earlier response. The paper also says continued treatment may lead to loss of efficacy and a treatment-unresponsive course. The claim’s “may” reflects that qualified account. (LLM, conf=0.91)
- Not checked yetcites [28] matched to “A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study)” (2012) source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Many of the STAR * D findings can be interpreted in light of the oppositional model of tolerance [32]: pharmacological manipulations, either by switching or augmentation (steps 1 and 2) may propel depressive illness into a refractory phase, characterized by low remission, high relapse, and high intolerance (steps 3 and 4).”
What the sources say
- Could not verifycites [32] matched to “Adaptive Treatment Strategies in Chronic Disease” (2008) sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Resistance to re-challenge, loss of clinical effects, paradoxical reactions, withdrawal and postwithdrawal syndromes tend to cluster and may share a common mechanism that has been subsumed under the rubric of oppositional model of tolerance [26, 32].”
What the sources say
- Supportedcites [26] matched to “Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience” (2018) source
The paper’s opening discussion says that withdrawal and other antidepressant-related phenomena may overlap in the same patient, and that these clinical manifestations may be unified under the oppositional model of tolerance. Its Pharmacological Strategies section also links withdrawal phenomena and persistent postwithdrawal disorders to manifestations of oppositional tolerance. (LLM, conf=0.91)
- Could not verifycites [32] matched to “Adaptive Treatment Strategies in Chronic Disease” (2008) sourceExperimental — accuracy not yet measured
The passages from the paper’s section on defining adaptive treatment strategies (page unavailable) discuss changing treatment in response to a patient’s condition, not an oppositional model of tolerance. Searches for that model, withdrawal and postwithdrawal syndromes, resistance to re-challenge, and paradoxical reactions found no passage addressing the claimed clustering or shared mechanism. (LLM, conf=0.75)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
58 more claims · 2 with their cited sources checked
Create a free account to see all 103 claims and to verify the 97 references still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 31
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This raises the possibility it may be mistaken for a “treatment-resistant” psychiatric condition.34”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [34]
In the citing paper
“Clinical outcome is the result of several interacting variables: living conditions, patient characteristics, illness features and previous therapeutic experience, self-management (the degree of collaboration of the patient in behavioural and lifestyle terms), and treatment setting (e.g. physician’s attitude and attention, illness behavior).”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Flawed Designs and Unwarranted Assumptions · p. 3
“pharmacological manipulations, either by switching or augmentation (steps 1 and 2)”
§ Flawed Designs and Unwarranted Assumptions · p. 3
“step 1 (open treatment with citalopram)”
Citations
Cites
The Need for a New Medical Model: A Challenge for Biomedicine
Engel, G. L. (1977) · Science · doi:10.1126/science.847460 · Cited by 12,887
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
How to measure comorbiditya critical review of available methods
DEGROOT, V, BECKERMAN, H., LANKHORST, G., & BOUTER, L. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00585-1 · Cited by 1,757
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation
(1948) · BMJ · doi:10.1136/bmj.2.4582.769 · Cited by 986
Depression: A cognitive perspective
LeMoult, J., & Gotlib, I. H. (2019) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.06.008 · Cited by 792
Problems in the “Evidence” of “Evidence-Based Medicine”
Feinstein, A. R., & Horwitz, R. I. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00244-1 · Cited by 653
A "SMART" Design for Building Individualized Treatment Sequences
Lei, H., Nahum-Shani, I., Lynch, K., Oslin, D., & Murphy, S. A. (2012) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032511-143152 · Cited by 557
Feinstein, A. R. (1987) · doi:10.2307/j.ctt1xp3vbc · Cited by 538
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521
COMFORT, EFFECTIVENESS, AND SELF-AWARENESS AS CRITERIA OF IMPROVEMENT IN PSYCHOTHERAPY
PARLOFF, M. B., KELMAN, H. C., & FRANK, J. D. (1954) · American Journal of Psychiatry · doi:10.1176/ajp.111.5.343 · Cited by 459
Treatment resistant depression: methodological overview and operational criteria
Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., & Mendlewicz, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00004-2 · Cited by 444
Wiles, N., Thomas, L., Abel, A., Ridgway, N., Turner, N., Campbell, J., Garland, A., Hollinghurst, S., Jerrom, B., Kessler, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61552-9 · Cited by 340
A Multidimensional Tool to Quantify Treatment Resistance in Depression: The Maudsley Staging Method
Fekadu, A., Wooderson, S., Donaldson, C., Markopoulou, K., Masterson, B., Poon, L., & Cleare, A. J. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04309 · Cited by 281
Cognitive behavioral treatment of residual symptoms in primary major depressive disorder
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.9.1295 · Cited by 266
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationCarrozzino, D., Patierno, C., Fava, G. A., & Guidi, J. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506879 · Cited by 263
Self-citationStaging: a neglected dimension in psychiatric classification
Fava, G. A., & Kellner, R. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03362.x · Cited by 252
Self-citationStaging of Mental Disorders: Systematic Review
Cosci, F., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000342243 · Cited by 235
Self-citationThe concept of recovery in major depression
FAVA, G. A., RUINI, C., & BELAISE, C. (2007) · Psychological Medicine · doi:10.1017/s0033291706008981 · Cited by 230
Self-citationMethodological Recommendations for Trials of Psychological Interventions
Guidi, J., Brakemeier, E.-L., Bockting, C. L. H., Cosci, F., Cuijpers, P., Jarrett, R. B., Linden, M., Marks, I., Peretti, C. S., Rafanelli, C., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000490574 · Cited by 205
Self-citation(1990) · PubMed · Cited by 199
Guidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167
Self-citationNew Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Self-citationMajor Depressive Disorder and Axis I Diagnostic Comorbidity
Zimmerman, M., Chelminski, I., & McDermut, W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0303 · Cited by 158
Memories of the British streptomycin trial in tuberculosis
Hill, S. A. B. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90001-i · Cited by 155
Fava, G. A., & Guidi, J. (2020) · World Psychiatry · doi:10.1002/wps.20698 · Cited by 148
Self-citationThe Clinical Process in Psychiatry: A Clinimetric Approach
Fava, G. A., Rafanelli, C., & Tomba, E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06444 · Cited by 143
Self-citationFava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
van Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
Maximizing Psychotherapy Outcome beyond Evidence-Based Medicine
Lambert, M. J. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000455170 · Cited by 123
Horwitz, R. I., Singer, B. H., Makuch, R. W., & Viscoli, C. M. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(95)00058-5 · Cited by 116
Adaptive Treatment Strategies in Chronic Disease
Lavori, P. W., & Dawson, R. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.062606.122232 · Cited by 113
Mood and Anxiety Disorders as Early Manifestations of Medical Illness: A Systematic Review
Cosci, F., Fava, G. A., & Sonino, N. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000367913 · Cited by 109
Self-citationRational Use of Antidepressant Drugs
Fava, G. A. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362803 · Cited by 95
Self-citationBschor, T., Kern, H., Henssler, J., & Baethge, C. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16r10749 · Cited by 94
Fava, G. A., Guidi, J., Rafanelli, C., & Rickels, K. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000480038 · Cited by 93
Self-citationCognitive-Behavioral Management of Drug-Resistant Major Depressive Disorder
Fava, G. A., Savron, G., Grandi, S., & Rafanelli, C. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0608b · Cited by 92
Self-citationFava, G. A., Ruini, C., Rafanelli, C., & Grandi, S. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.12.2094 · Cited by 88
Self-citationIatrogenic Factors in Psychopathology
Fava, G. A., & Rafanelli, C. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000500151 · Cited by 82
Self-citationFornaro, M., Anastasia, A., Novello, S., Fusco, A., Pariano, R., De Berardis, D., Solmi, M., Veronese, N., Stubbs, B., Vieta, E., et al. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.025 · Cited by 80
Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
Self-citationThornlow, D. K., Anderson, R., & Oddone, E. (2009) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2009.06.015 · Cited by 74
Treatment Approaches to Major Depressive Disorder Relapse
Schmidt, M. E., Fava, M., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063643 · Cited by 60
Cosci, F., & Fava, G. A. (2016) · CNS Spectrums · doi:10.1017/s1092852915000760 · Cited by 59
Self-citationRichardson, W. S., & Doster, L. M. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.10.020 · Cited by 55
Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000570 · Cited by 55
Self-citationSubtyping depression in the medically ill by cluster analysis
Guidi, J., Fava, G. A., Picardi, A., Porcelli, P., Bellomo, A., Grandi, S., Grassi, L., Pasquini, P., Quartesan, R., Rafanelli, C., et al. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.03.004 · Cited by 54
Self-citationDepression Associated with Medical Illness: Treatment Considerations
Fava, G. A., & Sonino, N. (1996) · CNS Drugs · doi:10.2165/00023210-199605030-00004 · Cited by 53
Self-citationTreatment-resistant depression: problematic illness or a problem in our approach?
Malhi, G. S., Das, P., Mannie, Z., & Irwin, L. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.246 · Cited by 53
Undurraga, J., & Baldessarini, R. J. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711709 · Cited by 49
Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on Adherence
De las Cuevas, C., & de Leon, J. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000450830 · Cited by 47
The Role of Staging in Planning Psychotherapeutic Interventions in Depression
Guidi, J., Tomba, E., Cosci, F., Park, S. K., & Fava, G. A. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16r10736 · Cited by 46
Self-citationTreatment Approaches to Major Depressive Disorder Relapse
Fava, M., Schmidt, M. E., Zhang, S., Gonzales, J., Raute, N. J., & Judge, R. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000063644 · Cited by 44
Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy
Fava, G. A., Tomba, E., & Tossani, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.014 · Cited by 41
Self-citationDold, M., Bartova, L., Rupprecht, R., & Kasper, S. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477770 · Cited by 38
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Hollinghurst, S., Carroll, F. E., Abel, A., Campbell, J., Garland, A., Jerrom, B., Kessler, D., Kuyken, W., Morrison, J., Ridgway, N., et al. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.125286 · Cited by 36
Treatment Selection in Depression: The Role of Clinical Judgment
Tomba, E., & Fava, G. A. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.003 · Cited by 35
Self-citationThe Biological and Biographical Basis of Precision Medicine
Lobitz, G. R., Armstrong, K., Concato, J., Singer, B. H., & Horwitz, R. I. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000502486 · Cited by 34
Variation in results from randomized, controlled trials: stochastic or systematic?
Jane-wit, D., Horwitz, R. I., & Concato, J. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.02.010 · Cited by 33
What is treatment resistance in psychiatry? A “difficult to treat” concept
Demyttenaere, K. (2019) · World Psychiatry · doi:10.1002/wps.20677 · Cited by 27
Fava, M., Martinez, J. M., Greist, J., Marangell, L. B., Brown, E., Chen, L., & Wohlreich, M. M. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701465178 · Cited by 25
Faravelli, C., Cosci, F., Ciampelli, M., Scarpato, M. A., Spiti, R., & Ricca, V. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000068689 · Cited by 22
Self-citationFabbri, S., Fava, G. A., Rafanelli, C., & Tomba, E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0904 · Cited by 21
Self-citationFailure to Respond after Reinstatement of Antidepressant Medication: A Systematic Review
Bosman, R. C., Waumans, R. C., Jacobs, G. E., Oude Voshaar, R. C., Muntingh, A. D. T., Batelaan, N. M., & van Balkom, A. J. L. M. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491550 · Cited by 21
Salloum, N. C., & Papakostas, G. I. (2019) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18r12250 · Cited by 21
Franchini, L., Rossini, D., Bongiorno, F., Spagnolo, C., Smeraldi, E., & Zanardi, R. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00188-8 · Cited by 20
Treatment-resistant depression
Simpson, G. M., & Kessel, J. B. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.159.1.162b · Cited by 11
A treatment should be evaluated by small trials
Borm, G. F., & Donders, R. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.03.006 · Cited by 10
Addressing Clinical Challenges of Antidepressant Discontinuation
Fava, G. A., & Cosci, F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18121419 · Cited by 10
Self-citationDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.01.026 · Cited by 9
Psychosocial management of treatment-resistant mood disorders: current evidence
Guidi, J., & Fava, G. A. (2015) · Treatment-Resistant Mood Disorders · doi:10.1093/med/9780198707998.003.0009 · Cited by 3
Self-citation
Research works printed but not linked: 1
- 3 Salloum NC, Papakostas GI. Staging treatment intensity and defining resistant depression. J Clin Psychiatry. 2019 Jun; 80: 18r12250.
Cited by
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Self-citationProdromal Symptoms in Depression: A Systematic Review
Benasi, G., Fava, G. A., & Guidi, J. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517953 · Cited by 73
Self-citationHengartner, M. P., Schulthess, L., Sorensen, A., & Framer, A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320980573 · Cited by 74
Framer, A. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125321991274 · Cited by 73
When Anxiety and Depression Coexist: The Role of Differential Diagnosis Using Clinimetric Criteria
Cosci, F., & Fava, G. A. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517518 · Cited by 63
Self-citation
Metadata
- Authors
- Fava, G. A., Cosci, F., Guidi, J., & Rafanelli, C.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Florence (IT)
- University of Bologna (IT)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 265-273
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3017554838
- Cited by
- 48
- References
- 75
- Citations by year
- 2025: 6 · 2024: 12 · 2023: 6 · 2022: 7 · 2021: 13 · 2020: 4
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment resistance, depression, antidepressant treatment, iatrogenic disease, misdiagnosis, diagnostic heterogeneity, biological heterogeneity, psychiatric comorbidity, treatment response assessment
- MeSH terms
- Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Resistance, Humans, Deception, Randomized Controlled Trials as Topic, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.